Health-related quality of life across all stages of autosomal dominant polycystic kidney disease
- PMID: 27662885
- PMCID: PMC5837636
- DOI: 10.1093/ndt/gfw335
Health-related quality of life across all stages of autosomal dominant polycystic kidney disease
Abstract
Background: A limited number of studies have assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease (ADPKD). Results to date have been conflicting and studies have generally focused on patients with later stages of the disease. This study aimed to assess HRQoL in ADPKD across all stages of the disease, from patients with early chronic kidney disease (CKD) to patients with end-stage renal disease.
Methods: A study involving cross-sectional patient-reported outcomes and retrospective clinical data was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Patients were enrolled into four mutually exclusive stages of the disease: CKD stages 1-3; CKD stages 4-5; transplant recipients; and dialysis patients.
Results: Overall HRQoL was generally highest in patients with CKD stages 1-3, followed by transplant recipients, patients with CKD stages 4-5 and patients on dialysis. Progressive disease predominately had an impact on physical health, whereas mental health showed less variation between stages of the disease. A substantial loss in quality of life was observed as patients progressed to CKD stages 4-5.
Conclusions: Later stages of ADPKD are associated with reduced physical health. The value of early treatment interventions that can delay progression of the disease should be considered.
Keywords: ADPKD; chronic kidney disease; patient-reported outcomes; polycystic kidney disease; quality of life.
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
Figures

Similar articles
-
Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.BMC Health Serv Res. 2017 Aug 15;17(1):560. doi: 10.1186/s12913-017-2513-8. BMC Health Serv Res. 2017. PMID: 28806944 Free PMC article.
-
Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.Kidney Med. 2024 Mar 24;6(5):100813. doi: 10.1016/j.xkme.2024.100813. eCollection 2024 May. Kidney Med. 2024. PMID: 38689835 Free PMC article.
-
Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe.BMC Nephrol. 2020 Jul 24;21(1):298. doi: 10.1186/s12882-020-01927-1. BMC Nephrol. 2020. PMID: 32709218 Free PMC article.
-
Outcomes of patients with autosomal-dominant polycystic kidney disease on peritoneal dialysis: A meta-analysis.Nephrology (Carlton). 2019 Jun;24(6):638-646. doi: 10.1111/nep.13431. Epub 2019 Apr 23. Nephrology (Carlton). 2019. PMID: 29952039
-
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.Trials. 2017 Nov 23;18(1):560. doi: 10.1186/s13063-017-2298-4. Trials. 2017. PMID: 29169385 Free PMC article.
Cited by
-
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.Kidney Med. 2023 Nov 27;6(1):100755. doi: 10.1016/j.xkme.2023.100755. eCollection 2024 Jan. Kidney Med. 2023. PMID: 38192435 Free PMC article.
-
Digital physical activity intervention via the Kidney BEAM platform in patients with polycystic kidney disease: a randomized controlled trial.Clin Kidney J. 2025 Feb 12;18(3):sfaf041. doi: 10.1093/ckj/sfaf041. eCollection 2025 Mar. Clin Kidney J. 2025. PMID: 40065847 Free PMC article.
-
Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.J Patient Rep Outcomes. 2018 Jul 13;2:30. doi: 10.1186/s41687-018-0055-4. eCollection 2018 Dec. J Patient Rep Outcomes. 2018. PMID: 30294710 Free PMC article.
-
Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review.Kidney360. 2024 Aug 1;5(8):1200-1206. doi: 10.34067/KID.0000000000000504. Epub 2024 Jul 8. Kidney360. 2024. PMID: 38976329 Free PMC article. Review.
-
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan.Kidney Med. 2020 Feb 26;2(2):162-171. doi: 10.1016/j.xkme.2019.11.008. eCollection 2020 Mar-Apr. Kidney Med. 2020. PMID: 32964204 Free PMC article.
References
-
- Neumann HP, Jilg C, Bacher J. et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant 2013; 28: 1472–1487 - PubMed
-
- Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477–1485 - PubMed
-
- Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287–1301 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous